November 26, 2024
FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM
The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) of Alnylam Pharmaceuticals’ vutrisiran for review.